WO1999022659A1 - Ring electrode structure for diagnostic and ablation catheters - Google Patents

Ring electrode structure for diagnostic and ablation catheters Download PDF

Info

Publication number
WO1999022659A1
WO1999022659A1 PCT/US1998/023520 US9823520W WO9922659A1 WO 1999022659 A1 WO1999022659 A1 WO 1999022659A1 US 9823520 W US9823520 W US 9823520W WO 9922659 A1 WO9922659 A1 WO 9922659A1
Authority
WO
WIPO (PCT)
Prior art keywords
electrode
catheter
tissue
ring
ring electrode
Prior art date
Application number
PCT/US1998/023520
Other languages
French (fr)
Inventor
Russell Collins
Michel Haissaguerre
Denyse Collins
Gary S. Falwell
Charles Gibson
Donald Patterson
Debbie Stevens-Wright
Sarkis Karakozian
Original Assignee
C.R. Bard, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C.R. Bard, Inc. filed Critical C.R. Bard, Inc.
Priority to CA002308278A priority Critical patent/CA2308278A1/en
Priority to JP2000518602A priority patent/JP2001521774A/en
Publication of WO1999022659A1 publication Critical patent/WO1999022659A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B18/1492Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/24Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/25Bioelectric electrodes therefor
    • A61B5/279Bioelectric electrodes therefor specially adapted for particular uses
    • A61B5/28Bioelectric electrodes therefor specially adapted for particular uses for electrocardiography [ECG]
    • A61B5/283Invasive
    • A61B5/287Holders for multiple electrodes, e.g. electrode catheters for electrophysiological study [EPS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/056Transvascular endocardial electrode systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345Vascular system
    • A61B2018/00351Heart
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00577Ablation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00791Temperature
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/06Measuring instruments not otherwise provided for
    • A61B2090/064Measuring instruments not otherwise provided for for measuring force, pressure or mechanical tension
    • A61B2090/065Measuring instruments not otherwise provided for for measuring force, pressure or mechanical tension for measuring contact or contact pressure

Definitions

  • This invention relates to diagnostic and ablation catheters and, more particularly, to a ring electrode structure for diagnostic and ablation catheters.
  • Cardiac dysrhythmias are commonly known as irregular heart beats or racing heart. Two such heart rhythm irregularities are the Wolff-Parkinson- White syndrome and A V nodal reentrant tachycardia. These conditions are caused by an extraneous strand of muscle fiber in the heart that provides an abnormal short-circuit pathway for electric impulses normally existing in the heart. For example, in one type of Wolff-Parkinson- White syndrome, the accessory pathway causes the electric impulses that normally travel from the upper to the lower chamber of the heart to be fed back to the upper chamber.
  • VT ventricular tachycardia
  • This latter type of cardiac dysrhythmia is a life-threatening arrhythmia.
  • Atrial fibrillation is the most commonly occurring type of arrhythmia. It is associated with increased morbidity and mortality due to a higher incidence of thromboembolic events and hemodynamic compromise.
  • AV atrioventricular
  • Pacemakers may be used to prevent recurrence of paroxysmal AF by either preventing the sinus bradycardia that triggers AF or reducing the interatrial conduction delay.
  • Non-surgical procedures such as management with drugs are favored in the treatment of cardiac dysrhythmias.
  • arrhythmias are not treatable with drugs, for example, disabling drug resistant AF, and have previously required surgery.
  • various incisions are made in the heart to block conduction pathways and thus divide the atrial area available for multiple wavelet reentry and abolish the arrhythmia.
  • an Automatic Implantable Cardioverter/Defibrillator can be surgically implanted into the patient, as described in U.S. Patent No.4,817.608 to Shapland et al. While these surgical procedures can be curative, they are associated with increased morbidity and mortality rates, and are extremely expensive. Even the use of an AICD requires major surgical intervention.
  • Non-surgical, minimally invasive techniques have been developed which are used to locate cardiac regions responsible for tachycardia, and also to disable the short-circuit function of these areas. According to these techniques, electrical energy shocks are applied to the endomyocardium to ablate cardiac tissue in the arrhythmogenic regions and produce scars which interrupt the reentrant conduction pathways.
  • the regions to be ablated are usually first determined by endocardiac mapping techniques. Mapping typically involves percutaneously introducing a diagnostic catheter having one or more electrodes into the patient, passing the diagnostic catheter through a blood vessel (e.g.
  • a tachycardial focus is located, as indicated in the electrocardiogram recording, it is marked by means of a fluoroscopic image so that cardiac arrhythmias at the located site can be ablated.
  • a conventional electrode catheter having electrodes with a greater surface-area than the diagnostic catheter's electrodes, can then provide electrical energy to the tissue adjacent the electrode to create a lesion in the tissue.
  • One or more suitably positioned lesions will create a region of necrotic tissue to disable the malfunction caused by the tachycardial focus.
  • Conventional catheter ablation techniques have used catheters each having a single electrode fitted at its tip as one electrical pole.
  • the other electrical pole is conventionally provided by a backplate in contact with a patient's external body part to form a capacitive coupling of the ablation energy source (DC, laser, RF, etc.).
  • ablation catheters are known in which multiple electrodes are provided, such as the catheter disclosed in allowed U.S. Patent Application Serial No. 08/569,771, filed December 8, 1995, of Mackey, the entirety of which is hereby incorporated by reference as if set forth herein.
  • ablation catheters having multiple electrodes are known, from, for example, U.S. Patent 5,779,669 to Haissaguerre, et al., the disclosure of which is hereby incorporated by reference as if set forth herein.
  • Ablation is effected by applying energy to the catheter electrodes once the electrodes are in contact with the cardiac tissue.
  • the energy can be, for example, RF, DC, ultrasound, microwave, or laser radiation.
  • RF energy is delivered between the distal tip of a standard electrode catheter and a backplate, there is a localized RF heating effect. This creates a well-defined, discrete lesion slightly larger than the tip electrode, and also causes the temperature of the tissue in contact with the electrode to rise.
  • the rising tissue temperature and changes in impedance at the electrode/tissue interface are sometimes monitored, as disclosed in the aforementioned Mackey patent, to better avoid undesirable complications such as tissue desiccation, blood coagulation, charring at the electrode, thrombus formation, or adhesion of the catheter to the tissue.
  • tissue desiccation blood coagulation
  • charring at the electrode
  • thrombus formation or adhesion of the catheter to the tissue.
  • saline-perfused catheters have been used to cool the tip electrode/tissue interface, thereby allowing more power to be delivered without the foregoing undesirable complications.
  • a ring electrode structure configured to map tachycardial foci and to form deep lesions in tissue without unduly heating the tissue at the electrode/tissue interface.
  • a multielectrode catheter having such an electrode structure with the electrodes being axially spaced from one another for enhanced diagnostic and ablation applications, without sacrificing catheter flexibility.
  • a ring electrode structure which has a raised radial dimension such that the electrode projects from the outer diameter of the catheter when mounted thereon.
  • the outer diameter of the electrode exceeds that of the catheter on which it is mounted.
  • the raised or upstanding ring electrode has a tissue contacting surface that generally contacts tissue within a patient before the catheter itself comes into contact with the tissue.
  • This arrangement ensures good and uniform tissue contact for each electrode mounted on the distal end of a catheter.
  • This arrangement also enables greater pressure to be applied to this tissue with a reduced force as compared to a conventional electrode catheter configuration, due to the reduced contact area presented by the upstanding ring electrode.
  • the ring electrode projects from the catheter on which it is mounted by between about 0.25 french and about 2 french.
  • the upstanding electrode has smooth, curved edges to prevent tissue damage when the catheter is advanced and withdrawn from a patient.
  • Fig. 1 illustrates, in plan view, the ring electrode structure of the present invention supported on an ablation catheter
  • Fig. 2 is a cross-sectional view taken along lines 2-2 of Fig. 1 ;
  • Fig.3 is a cross sectional view of a modified ring electrode structure according to the present invention.
  • Fig. 4 illustrates the results of an in vitro comparative ablation experiment in which ablation energy was applied for 60 seconds and controlled to not exceed 65 °C;
  • Fig. 5 illustrates the results of an in vitro comparative ablation experiment in which ablation energy was applied for 90 seconds and controlled to not exceed 65 °C;
  • Fig. 6 illustrates the results of an in vitro comparative ablation experiment in which ablation energy was applied for 120 seconds and controlled to not exceed 65 °C.
  • a ring electrode structure 10 supported on a combination diagnostic (mapping) and ablation catheter 12, along a distal portion 14 thereof.
  • a tip electrode 16 is provided at the catheter distal end, which may be of conventional design.
  • a particularly suitable assembly for the distal tip electrode 16 is described in U.S. Patent No. 5,685,878, issued November 11, 1997, which is hereby incorporated by reference as if set forth in its entirety herein.
  • the tip electrode 16 is made of platinum and is attached directly to the distal end of the catheter 12.
  • a refractive material may be interposed between the tip electrode 16 (or the other electrodes) and the catheter 12 to protect the supporting catheter from heat during and just after ablation energy has been applied to the electrodes 10,16.
  • the ring electrode structure 10 preferably has the same inner diameter as a conventional electrode, that is, slightly smaller than the outer diameter of the catheter 12.
  • Each ring electrode is mountable on the catheter 12, for example, by threading a conductive wire 18 soldered or welded to the electrode 10 into a lumen 20 of the catheter through an aperture 22, temporarily stretching the distal portion 14 of the catheter to neck down its outer diameter, slipping the ring electrode 10 over the catheter 12, and releasing the tension on the catheter once the ring electrode is positioned over the aperture 22 (see Fig.2).
  • each ring electrode 10 preferably has a temperature sensor 23 mounted along its inner diameter which is seated against the catheter 12, preferably within a cavity in the outer wall of the catheter or in register with the aperture 22, when the ring electrode 10 is mounted to the catheter.
  • the temperature sensor 23 can be a thermocouple, thermistor, or resistive thermal device ("RTD").
  • Each temperature sensor 23 has an associated conductive lead (not shown) which also extends proximally to the connector.
  • the ring electrode 10 has a thickness, as measured in the radial direction R (see Fig. 2), sufficient to cause a contact surface 24 thereof to project from the catheter 12.
  • the contact surface 24 generally contacts tissue 26 before the catheter 12 comes into contact with the tissue, even at locations where the tissue has an irregular surface.
  • a force is applied in a conventional manner from the proximal end 28 of the catheter 12 to press the electrodes 10, 16 against the tissue 26.
  • the upstanding electrodes concentrate the points of tissue contact on the surfaces 24 rather than on the insulating portions 30 of the distal portion 14 of the catheter.
  • conventional electrode designs are flush with the outer diameter of the catheter and therefore present a significantly greater contact area with the tissue 26.
  • the upstanding ring electrodes 10 of the present invention achieve comparable pressure as is achieved in conventional designs with significantly less applied force. This provides benefits for both mapping and ablation procedures.
  • a catheter which includes the electrode 10 is less sensitive to less than optimum tissue contact pressure situations because more electrode surface area of the upstanding electrodes is available to contact the tissue, more RF energy is radiated from the electrode 10, particularly at the electrode edges, and there is a greater likelihood that the electrode will affirmatively engage an irregular tissue surface and focus the contact pressure at the electrodes 10 instead spreading a lessened pressure over a greater contact area which includes both electrodes and the insulative regions 30 (as in conventional designs).
  • the upstanding ring electrodes 10 enable significantly deeper and wider lesions to be formed (as taken along the z- and y-axes of Fig. 1, respectively) than conventional electrode designs permit for the same degree of surface tissue temperature and ablation time.
  • Each of the ring electrodes was of the same length (4 mm. as taken along the x-axis of Fig. 1) and was mounted on a separate catheter (having an outside diameter of 91 mils (7 French)).
  • thermocouple was attached to the inside diameter of each ring electrode at the electrode centerline for sensing the surface tissue temperature. Once mounted, the conventional electrode was flush with the catheter, and the upstanding ring electrode 10 projected by approximately fifteen mils (that is, more than one French). Fifteen grams of force was applied to each electrode to hold it in contact with a tissue sample, and using controlled temperature feedback set to 65 °C, energy was delivered to the electrodes for sixty seconds while 1400 ml/min of saline was flowed.
  • the in vitro experiment examined lesion results on a tissue specimen comprising a transverse cross-section of bovine striated muscle tissue approximately 1" long, 0.75" wide, and 0.50" deep.
  • An immersible fixture was used to position the electrode with its thermocouple-bearing side was in contact with the tissue specimen.
  • fifteen grams of weight was applied to the catheter shaft on either side of the electrode to ensure that the electrode was held firmly against the specimen.
  • the fixture enables controlled placement and alignment of an additional thermocouple within the specimen directly below the axial and radial center of the electrode.
  • the assembly was submerged in a tank of 37 °C saline/DI water mixture balanced to a 100 ⁇ initial impedance and circulated at 1400 ml/min by a peristaltic pump.
  • the ablation procedure and data collection commenced after the assembly equilibriated with the saline/DI water mixture.
  • Ablation energy was applied to the specimen for a predetermined duration
  • D is the cross-sectional depth from the center point of the surface burn to the deepest margin of the lesion
  • W is the surface width
  • L is the cross-sectional length at the longest margin
  • the calculated lesion volume is equal to ( ⁇ /6)(DWL):
  • the upstanding electrode according to the invention outperformed me conventional electrode for each parameter that was measured, as shown in Figs. 4-6 which illustrate the results for three different ablation duration cycles (60, 90 and 120 second cycles, respectively), wherein the "thick" electrode is the electrode 10 and the "thin” electrode is the conventional electrode.
  • the ring electrode structure 10 allows more power delivery to better promote lesion formation, as compared to conventional electrode constructions, without increasing tissue surface temperature beyond a clinically acceptable level. Further, enhanced power delivery was obtained without increasing the length of the electrode and without compromising catheter flexibility. As a result, the ring electrodes 10 can be provided with a thickness and axial length suitable for high power ablation.
  • the ring electrodes 10 have a smaller contact area than conventional, flush electrodes, they are also suitable for mapping tachycardial foci without blurring the situs of the sensed signal.
  • the smaller contact surface 24 of the ring electrode 10 enables both fine signal sensing (like a small antenna), and ablation.
  • the power to the electrode 10 may be delivered for durations of about 120 seconds or less to reduce the risk of the electrode 10 adhering to the tissue being ablated and to minimize any tendency that the tissue may have to wrap around the tissue, for example, as a result of tissue dessication.
  • the ablation time is increased above, for example, sixty seconds, the lesion cross-sections were observed as being progressively more dense and rubbery to the touch, which may be an indication of increased tissue dessication and a concomitant rise in lesion density. This suggests that the final lesion volume which was measured is less than the actual volume of tissue that was affected by the procedure, particularly in the case of the longer ablation energy cycle durations.
  • Fig. 3 illustrates a modification of the ring electrode illustrated in Fig. 1.
  • the ring electrode 10' lacks any sharp edges that may cause tissue damage when the catheter 12 is moved within a patient.
  • the ring electrode 10' has smooth, curved edges.
  • a sheath can be used with this embodiment or the embodiment of Fig. 1 to ensure atruamatic delivery and retraction of the catheter 12.
  • the catheter 12 may support only one or an arbitrarily large number of ring electrodes 10.
  • the ring electrodes 10 are spaced from each other (and the tip electrode 16) by insulative regions 30, and each can be of an arbitrary axial length.
  • the electrodes may be spaced, for example, 1 to 3 mm apart, depending on the thickness of the electrode (as measured in the radial direction) and the range of power to be applied.
  • the electrode spacing can also be established with regard to diagnostic considerations such that the electrodes are suitably spaced to map electrical signals within the heart.
  • the increased lesion volume resulting from the ring electrode structure of the present invention permits an increase in the inter- electrode spacing along the distal end of the catheter shaft and/or a reduction in the electrode's axial length without sacrificing the ability to create a continuous, linear lesion in the regions between the electrodes 10, that is, beneath insulative regions 30.
  • the electrode structure of the present invention permits an increase in tip flexibility by exposing more of the insulative regions 30 of the catheter 12.
  • the thickness of the ring electrode 10 may be selected to ensure that the ring electrode has approximately the same mass as the tip electrode 16 or some other predetermined mass. As described above, it is generally desirable to have an axially short electrode 10 so that the focus of a tachycardia signal is not blurred across the length of the electrode. However, the electrode 10 cannot be made to project from the catheter too far or else the catheter will not be readily maneuverable into a desired passageway. Accordingly, a designer must strike a balance between the axial length of the ring electrode 10 and its radial thickness to achieve a predetermined mass.
  • the mass of the ring electrode is made to generally match that of the tip electrode 16, and more preferably to substantially match the mass of the tip electrode.
  • the arrhythmogenic site is determined by positioning the distal portion 14 of the catheter 12 in the heart and sensing the electrical signals using the ring electrodes 10. Once the arrhythmogenic site is located, a power supply (not shown) is configured to energize the electrodes 10, 16 in either a constant voltage, power, or temperature mode as described in detail in the aforementioned Mackey patent. The electrodes can be energized simultaneously, sequentially, or in accordance with some other pattern. Radio- frequency energy in the range typically of about 250 Khz to 500 Khz is delivered to the electrodes 10,16 to ablate tissue.
  • a catheter in accordance with the invention can be packaged with a guide sheath which is sized to accommodate the ring electrodes 10.
  • the guide sheath can be a conventional 8 Fr guide, or may be a custom guide sheath which is sized larger than 7.5 Fr.

Abstract

A ring electrode structure having a raised radial dimension. The electrode projects from the outer diameter of the catheter when mounted thereon. The upstanding ring electrode has a tissue contacting surface that generally contacts tissue within a patient before the catheter itself comes into contact with the tissue. The electrode ensures good and uniform tissue contact for each electrode mounted on the distal end of a catheter. The electrode also enables greater pressure to be applied to this tissue with a reduced force as compared to a conventional electrode catheter configuration, due to the reduced contact area presented by the upstanding ring electrode. In a preferred configuration, the upstanding electrode has smooth, curved edges to prevent tissue damage when the catheter is advanced and withdrawn from a patient.

Description

RING ELECTRODE STRUCTURE FOR DIAGNOSTIC AND ABLATION CATHETERS
Field of the Invention This invention relates to diagnostic and ablation catheters and, more particularly, to a ring electrode structure for diagnostic and ablation catheters.
Background of the Invention
Cardiac dysrhythmias are commonly known as irregular heart beats or racing heart. Two such heart rhythm irregularities are the Wolff-Parkinson- White syndrome and A V nodal reentrant tachycardia. These conditions are caused by an extraneous strand of muscle fiber in the heart that provides an abnormal short-circuit pathway for electric impulses normally existing in the heart. For example, in one type of Wolff-Parkinson- White syndrome, the accessory pathway causes the electric impulses that normally travel from the upper to the lower chamber of the heart to be fed back to the upper chamber. Another common type of cardiac dysrhythmia is ventricular tachycardia (VT), which may be a complication of a heart attack or reduction of blood supply to an area of heart muscle. This latter type of cardiac dysrhythmia is a life-threatening arrhythmia.
Atrial fibrillation (AF) is the most commonly occurring type of arrhythmia. It is associated with increased morbidity and mortality due to a higher incidence of thromboembolic events and hemodynamic compromise. In patients with disabling drug resistant AF, the ventricular response can be controlled by catheter ablation or modification of the atrioventricular (AV) nodal region, but this procedure is palliative since AF and its related risks persist afterwards. Pacemakers may be used to prevent recurrence of paroxysmal AF by either preventing the sinus bradycardia that triggers AF or reducing the interatrial conduction delay.
Non-surgical procedures such as management with drugs are favored in the treatment of cardiac dysrhythmias. However, some arrhythmias are not treatable with drugs, for example, disabling drug resistant AF, and have previously required surgery. According to these procedures, various incisions are made in the heart to block conduction pathways and thus divide the atrial area available for multiple wavelet reentry and abolish the arrhythmia. Alternatively, an Automatic Implantable Cardioverter/Defibrillator (AICD) can be surgically implanted into the patient, as described in U.S. Patent No.4,817.608 to Shapland et al. While these surgical procedures can be curative, they are associated with increased morbidity and mortality rates, and are extremely expensive. Even the use of an AICD requires major surgical intervention. However, patients of advanced age or illness, for example, cannot tolerate invasive surgery to excise the tachycardia focus which causes dysrhythmias. Non-surgical, minimally invasive techniques have been developed which are used to locate cardiac regions responsible for tachycardia, and also to disable the short-circuit function of these areas. According to these techniques, electrical energy shocks are applied to the endomyocardium to ablate cardiac tissue in the arrhythmogenic regions and produce scars which interrupt the reentrant conduction pathways. The regions to be ablated are usually first determined by endocardiac mapping techniques. Mapping typically involves percutaneously introducing a diagnostic catheter having one or more electrodes into the patient, passing the diagnostic catheter through a blood vessel (e.g. the femoral vein or aorta) and into an endocardiac site (e.g., the atrium or ventricle of the heart), and inducing a tachycardia so that a continuous, simultaneous recording can be made with a multichannel recorder at each of several different endocardiac positions. When a tachycardial focus is located, as indicated in the electrocardiogram recording, it is marked by means of a fluoroscopic image so that cardiac arrhythmias at the located site can be ablated. A conventional electrode catheter, having electrodes with a greater surface-area than the diagnostic catheter's electrodes, can then provide electrical energy to the tissue adjacent the electrode to create a lesion in the tissue. One or more suitably positioned lesions will create a region of necrotic tissue to disable the malfunction caused by the tachycardial focus. Conventional catheter ablation techniques have used catheters each having a single electrode fitted at its tip as one electrical pole. The other electrical pole is conventionally provided by a backplate in contact with a patient's external body part to form a capacitive coupling of the ablation energy source (DC, laser, RF, etc.). Other ablation catheters are known in which multiple electrodes are provided, such as the catheter disclosed in allowed U.S. Patent Application Serial No. 08/569,771, filed December 8, 1995, of Mackey, the entirety of which is hereby incorporated by reference as if set forth herein. Still other ablation catheters having multiple electrodes are known, from, for example, U.S. Patent 5,779,669 to Haissaguerre, et al., the disclosure of which is hereby incorporated by reference as if set forth herein. Ablation is effected by applying energy to the catheter electrodes once the electrodes are in contact with the cardiac tissue. The energy can be, for example, RF, DC, ultrasound, microwave, or laser radiation. When RF energy is delivered between the distal tip of a standard electrode catheter and a backplate, there is a localized RF heating effect. This creates a well-defined, discrete lesion slightly larger than the tip electrode, and also causes the temperature of the tissue in contact with the electrode to rise. The rising tissue temperature and changes in impedance at the electrode/tissue interface are sometimes monitored, as disclosed in the aforementioned Mackey patent, to better avoid undesirable complications such as tissue desiccation, blood coagulation, charring at the electrode, thrombus formation, or adhesion of the catheter to the tissue. To stem rising temperature, saline-perfused catheters have been used to cool the tip electrode/tissue interface, thereby allowing more power to be delivered without the foregoing undesirable complications.
The small size and shallow depth of the lesions produced by RF ablation has been perceived as one of the limitations of this technique. Conventional thinking has been that a large contact region is required to create either a sufficiently large or deep lesion using RF to block ventricular tachycardia. Along this line of thought, improvements in electrode design have concerned changes in the length of the electrode, as viewed in the direction of elongation of the catheter. Proposed elongated electrodes have been six, eight, ten or even twelve millimeters in length to promote longer lesion formation and to allow more power to be delivered to the tissue through increased contact area. However, attendant with increased electrode length is a decrease in the flexibility of the catheter on which such elongated electrodes are mounted and a concomitant increase in the risk of myocardial wall perforation and morbidity rate.
In addition, an unresolved problem remains how to ensure good and uniform tissue contact at each of the elongated electrodes at the distal end of the catheter. Complicating this problem is the fact that the endomyocardium, and the pectinate muscles of the atrium in particular, have an irregular surface. Therefore, contact pressure must be applied to each of the electrodes over the length of the catheter that supports the electrodes to ensure that each electrode makes good contact with tissue.
What is needed in the art and has heretofore not been available is a ring electrode structure configured to map tachycardial foci and to form deep lesions in tissue without unduly heating the tissue at the electrode/tissue interface. What is further needed in the art is a multielectrode catheter having such an electrode structure with the electrodes being axially spaced from one another for enhanced diagnostic and ablation applications, without sacrificing catheter flexibility.
Summary of the Invention
According to one aspect of the invention, a ring electrode structure is disclosed which has a raised radial dimension such that the electrode projects from the outer diameter of the catheter when mounted thereon. In other words, the outer diameter of the electrode exceeds that of the catheter on which it is mounted. The raised or upstanding ring electrode has a tissue contacting surface that generally contacts tissue within a patient before the catheter itself comes into contact with the tissue. This arrangement ensures good and uniform tissue contact for each electrode mounted on the distal end of a catheter. This arrangement also enables greater pressure to be applied to this tissue with a reduced force as compared to a conventional electrode catheter configuration, due to the reduced contact area presented by the upstanding ring electrode. Preferably, the ring electrode projects from the catheter on which it is mounted by between about 0.25 french and about 2 french.
In accordance with another aspect of the invention, the upstanding electrode has smooth, curved edges to prevent tissue damage when the catheter is advanced and withdrawn from a patient. Description of the Drawings
Other objects and aspects of the invention should be apparent from the following detailed description of the preferred embodiments taken in conjunction with the following drawings in which:
Fig. 1 illustrates, in plan view, the ring electrode structure of the present invention supported on an ablation catheter;
Fig. 2 is a cross-sectional view taken along lines 2-2 of Fig. 1 ;
Fig.3 is a cross sectional view of a modified ring electrode structure according to the present invention;
Fig. 4 illustrates the results of an in vitro comparative ablation experiment in which ablation energy was applied for 60 seconds and controlled to not exceed 65 °C;
Fig. 5 illustrates the results of an in vitro comparative ablation experiment in which ablation energy was applied for 90 seconds and controlled to not exceed 65 °C; and
Fig. 6 illustrates the results of an in vitro comparative ablation experiment in which ablation energy was applied for 120 seconds and controlled to not exceed 65 °C.
Detailed Description of the Preferred Embodiments
By way of overview and introduction, there is seen in Fig. 1 a ring electrode structure 10 according to the invention supported on a combination diagnostic (mapping) and ablation catheter 12, along a distal portion 14 thereof. Preferably, a tip electrode 16 is provided at the catheter distal end, which may be of conventional design. A particularly suitable assembly for the distal tip electrode 16 is described in U.S. Patent No. 5,685,878, issued November 11, 1997, which is hereby incorporated by reference as if set forth in its entirety herein. Conventionally, the tip electrode 16 is made of platinum and is attached directly to the distal end of the catheter 12. Alternatively, a refractive material (not shown) may be interposed between the tip electrode 16 (or the other electrodes) and the catheter 12 to protect the supporting catheter from heat during and just after ablation energy has been applied to the electrodes 10,16.
The ring electrode structure 10 preferably has the same inner diameter as a conventional electrode, that is, slightly smaller than the outer diameter of the catheter 12. Each ring electrode is mountable on the catheter 12, for example, by threading a conductive wire 18 soldered or welded to the electrode 10 into a lumen 20 of the catheter through an aperture 22, temporarily stretching the distal portion 14 of the catheter to neck down its outer diameter, slipping the ring electrode 10 over the catheter 12, and releasing the tension on the catheter once the ring electrode is positioned over the aperture 22 (see Fig.2). Also, each ring electrode 10 preferably has a temperature sensor 23 mounted along its inner diameter which is seated against the catheter 12, preferably within a cavity in the outer wall of the catheter or in register with the aperture 22, when the ring electrode 10 is mounted to the catheter. The temperature sensor 23 can be a thermocouple, thermistor, or resistive thermal device ("RTD"). Each temperature sensor 23 has an associated conductive lead (not shown) which also extends proximally to the connector.
In accordance with the present invention, the ring electrode 10 has a thickness, as measured in the radial direction R (see Fig. 2), sufficient to cause a contact surface 24 thereof to project from the catheter 12. As a result, the contact surface 24 generally contacts tissue 26 before the catheter 12 comes into contact with the tissue, even at locations where the tissue has an irregular surface. To ensure good tissue contact, a force is applied in a conventional manner from the proximal end 28 of the catheter 12 to press the electrodes 10, 16 against the tissue 26. The upstanding electrodes concentrate the points of tissue contact on the surfaces 24 rather than on the insulating portions 30 of the distal portion 14 of the catheter. In contrast, conventional electrode designs are flush with the outer diameter of the catheter and therefore present a significantly greater contact area with the tissue 26. Because applied pressure is inversely related to the size of the contact area (P=F/A), the upstanding ring electrodes 10 of the present invention achieve comparable pressure as is achieved in conventional designs with significantly less applied force. This provides benefits for both mapping and ablation procedures. For example, a catheter which includes the electrode 10 is less sensitive to less than optimum tissue contact pressure situations because more electrode surface area of the upstanding electrodes is available to contact the tissue, more RF energy is radiated from the electrode 10, particularly at the electrode edges, and there is a greater likelihood that the electrode will affirmatively engage an irregular tissue surface and focus the contact pressure at the electrodes 10 instead spreading a lessened pressure over a greater contact area which includes both electrodes and the insulative regions 30 (as in conventional designs). Surprisingly, the upstanding ring electrodes 10 enable significantly deeper and wider lesions to be formed (as taken along the z- and y-axes of Fig. 1, respectively) than conventional electrode designs permit for the same degree of surface tissue temperature and ablation time. An in vitro experiment was performed in which the volume of a lesion produced using a conventional electrode (2.5 mils thick) mounted flush with a catheter was compared with the volume of lesion formed using an upstanding ring electrode (10 mils thick) according to the present invention. (1 mil= 0.0254 mm.) Each of the ring electrodes was of the same length (4 mm. as taken along the x-axis of Fig. 1) and was mounted on a separate catheter (having an outside diameter of 91 mils (7 French)). A thermocouple was attached to the inside diameter of each ring electrode at the electrode centerline for sensing the surface tissue temperature. Once mounted, the conventional electrode was flush with the catheter, and the upstanding ring electrode 10 projected by approximately fifteen mils (that is, more than one French). Fifteen grams of force was applied to each electrode to hold it in contact with a tissue sample, and using controlled temperature feedback set to 65 °C, energy was delivered to the electrodes for sixty seconds while 1400 ml/min of saline was flowed.
More particularly, the in vitro experiment examined lesion results on a tissue specimen comprising a transverse cross-section of bovine striated muscle tissue approximately 1" long, 0.75" wide, and 0.50" deep. An immersible fixture was used to position the electrode with its thermocouple-bearing side was in contact with the tissue specimen. In addition, fifteen grams of weight was applied to the catheter shaft on either side of the electrode to ensure that the electrode was held firmly against the specimen. The fixture enables controlled placement and alignment of an additional thermocouple within the specimen directly below the axial and radial center of the electrode.
With the tissue specimen and electrode mounted and supported as described above, the assembly was submerged in a tank of 37 °C saline/DI water mixture balanced to a 100Ω initial impedance and circulated at 1400 ml/min by a peristaltic pump. The ablation procedure and data collection commenced after the assembly equilibriated with the saline/DI water mixture. Ablation energy was applied to the specimen for a predetermined duration
(e.g., 60 sec. 90 sec, and 120 sec.) in a temperature controlled mode with a 65 °C set-point.
A comparative test of the electrode 10 according to the invention and a conventional electrode was then performed using Radionics brand Lesion Generators (Model
3E), with personal computers attached thereto, to control the ablation procedure and capture the lesion parameter data. The results are shown below: D W L Lesion volume
Conventional electrode 4.3 4.6 7.6 82.4 mm3
Upstanding electrode 6.0 6.6 8.3 180 mm3
wherein D is the cross-sectional depth from the center point of the surface burn to the deepest margin of the lesion, W is the surface width, L is the cross-sectional length at the longest margin, and the calculated lesion volume is equal to (π/6)(DWL):
The upstanding electrode according to the invention outperformed me conventional electrode for each parameter that was measured, as shown in Figs. 4-6 which illustrate the results for three different ablation duration cycles (60, 90 and 120 second cycles, respectively), wherein the "thick" electrode is the electrode 10 and the "thin" electrode is the conventional electrode.
To achieve the results obtained with the electrode 10, a conventional electrode would have to be energized for a greater period of time, or a higher surface tissue temperature would have to be tolerated along with greater risk of tissue desiccation, electrode charring, blood coagulation, and the like. Thus, the ring electrode structure 10 allows more power delivery to better promote lesion formation, as compared to conventional electrode constructions, without increasing tissue surface temperature beyond a clinically acceptable level. Further, enhanced power delivery was obtained without increasing the length of the electrode and without compromising catheter flexibility. As a result, the ring electrodes 10 can be provided with a thickness and axial length suitable for high power ablation. Because the ring electrodes 10 have a smaller contact area than conventional, flush electrodes, they are also suitable for mapping tachycardial foci without blurring the situs of the sensed signal. The smaller contact surface 24 of the ring electrode 10 enables both fine signal sensing (like a small antenna), and ablation.
The power to the electrode 10 may be delivered for durations of about 120 seconds or less to reduce the risk of the electrode 10 adhering to the tissue being ablated and to minimize any tendency that the tissue may have to wrap around the tissue, for example, as a result of tissue dessication. As the ablation time is increased above, for example, sixty seconds, the lesion cross-sections were observed as being progressively more dense and rubbery to the touch, which may be an indication of increased tissue dessication and a concomitant rise in lesion density. This suggests that the final lesion volume which was measured is less than the actual volume of tissue that was affected by the procedure, particularly in the case of the longer ablation energy cycle durations.
Fig. 3 illustrates a modification of the ring electrode illustrated in Fig. 1. In Fig. 3, the ring electrode 10' lacks any sharp edges that may cause tissue damage when the catheter 12 is moved within a patient. Specifically, the ring electrode 10' has smooth, curved edges. Of course, a sheath can be used with this embodiment or the embodiment of Fig. 1 to ensure atruamatic delivery and retraction of the catheter 12.
While two ring electrodes 10 are shown spaced in serial manner along the catheter 12, the catheter 12 may support only one or an arbitrarily large number of ring electrodes 10. The ring electrodes 10 are spaced from each other (and the tip electrode 16) by insulative regions 30, and each can be of an arbitrary axial length. To create linear lesions during ablation, the electrodes may be spaced, for example, 1 to 3 mm apart, depending on the thickness of the electrode (as measured in the radial direction) and the range of power to be applied. The electrode spacing can also be established with regard to diagnostic considerations such that the electrodes are suitably spaced to map electrical signals within the heart.
As compared to conventional electrodes, the increased lesion volume resulting from the ring electrode structure of the present invention permits an increase in the inter- electrode spacing along the distal end of the catheter shaft and/or a reduction in the electrode's axial length without sacrificing the ability to create a continuous, linear lesion in the regions between the electrodes 10, that is, beneath insulative regions 30. Whether the inter-electrode spacing is increased or whether the electrode is axially shortened, the electrode structure of the present invention permits an increase in tip flexibility by exposing more of the insulative regions 30 of the catheter 12. The radial thickness of the ring electrode 10 multiplied by its axial length, that is, its length along the x-axis in Fig. 1 (which corresponds to the direction of elongation of the catheter), defines the mass of the ring electrode. The thickness of the ring electrode 10 may be selected to ensure that the ring electrode has approximately the same mass as the tip electrode 16 or some other predetermined mass. As described above, it is generally desirable to have an axially short electrode 10 so that the focus of a tachycardia signal is not blurred across the length of the electrode. However, the electrode 10 cannot be made to project from the catheter too far or else the catheter will not be readily maneuverable into a desired passageway. Accordingly, a designer must strike a balance between the axial length of the ring electrode 10 and its radial thickness to achieve a predetermined mass. Preferably, the mass of the ring electrode is made to generally match that of the tip electrode 16, and more preferably to substantially match the mass of the tip electrode. In operation, the arrhythmogenic site is determined by positioning the distal portion 14 of the catheter 12 in the heart and sensing the electrical signals using the ring electrodes 10. Once the arrhythmogenic site is located, a power supply (not shown) is configured to energize the electrodes 10, 16 in either a constant voltage, power, or temperature mode as described in detail in the aforementioned Mackey patent. The electrodes can be energized simultaneously, sequentially, or in accordance with some other pattern. Radio- frequency energy in the range typically of about 250 Khz to 500 Khz is delivered to the electrodes 10,16 to ablate tissue. Energy flows from the electrodes 10,16 through the tissue 26 to a return plate, which is connected to the ground potential of the power supply, to complete the circuit. The flow of current through the circuit to the tissue 26 causes heating which results in the destruction of the tissue 26 near the electrodes 10, 16, and ideally the arrhythmogenic site. If performed successfully, permanent interruption of the arrhythmia occurs and the patient is cured.
A catheter in accordance with the invention can be packaged with a guide sheath which is sized to accommodate the ring electrodes 10. Thus, if a 7 Fr catheter is provided with 7.5 Fr ring electrodes 10, then the guide sheath can be a conventional 8 Fr guide, or may be a custom guide sheath which is sized larger than 7.5 Fr.
Having thus described preferred embodiments of the present invention, it is to be understood that the above described arrangement and system is merely illustrative of the principles of the present invention, and that other arrangements and systems may be devised by those skilled in the art without departing from the spirit and scope of the invention as claimed below.

Claims

We Claim: 1. An electrode catheter for ablating tissue within a patient, comprising: an elongated catheter including a distal portion having a predetermined outside diameter and a lumen therein; at least one ring electrode supported on the distal portion; a conductive wire disposed within the lumen and having one end connected to the ring electrode; a temperature sensor disposed beneath the ring electrode, wherein the ring electrode has a thickness such that the electrode projects in a direction generally transverse to the direction of elongation of the catheter by a distance which is sufficient to space the distal portion of the catheter from the tissue to be ablated.
2. The electrode catheter as in Claim 1 , wherein the ring electrode has an inner diameter smaller than the predetermined outer diameter of the catheter.
3. The electrode catheter as in Claim 1, wherein the temperature sensor is selected from the group consisting of a thermocouple, a thermistor, and a resistive thermal device.
4. The electrode catheter as in Claim 1 , wherein the ring electrode projects from the catheter 4 mils or more in the radial direction.
5. The electrode catheter as in Claim 1, wherein the ring electrode has smooth, curved edges.
6. The electrode catheter as in Claim 1 , wherein there are plural ring electrodes supported on the catheter.
7. The electrode catheter as in Claim 1, wherein the catheter has a slot sized to accommodate the temperature sensor and permit the ring electrode to be coaxially supported on the catheter.
8. The electrode catheter as in Claim 7, wherein the ring electrodes are spaced in the direction of elongation of the catheter by insulative regions.
9. The electrode catheter as in Claim 1 , further comprising a tip electrode at a distal tip of the catheter.
10. The electrode catheter as in Claim 9, further comprising a refractive element interposed between the distal tip of the catheter and the tip electrode.
11. The electrode catheter as in claim 1 , wherein the ring electrode has a length in the direction of elongation of the catheter and wherein the thickness of the ring electrode is selected such that its length times its thickness is equal to a predetermined mass.
12. The electrode catheter as in claim 11 , further comprising a tip electrode having a mass at a distal tip of the catheter, wherein the mass of the tip electrode is substantially equal to the predetermined mass.
PCT/US1998/023520 1997-10-31 1998-10-30 Ring electrode structure for diagnostic and ablation catheters WO1999022659A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002308278A CA2308278A1 (en) 1997-10-31 1998-10-30 Ring electrode structure for diagnostic and ablation catheters
JP2000518602A JP2001521774A (en) 1997-10-31 1998-10-30 Ring-shaped electrode structure for diagnostic and ablation catheters

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6382397P 1997-10-31 1997-10-31
US60/063,823 1997-10-31

Publications (1)

Publication Number Publication Date
WO1999022659A1 true WO1999022659A1 (en) 1999-05-14

Family

ID=22051747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/023520 WO1999022659A1 (en) 1997-10-31 1998-10-30 Ring electrode structure for diagnostic and ablation catheters

Country Status (3)

Country Link
JP (1) JP2001521774A (en)
CA (1) CA2308278A1 (en)
WO (1) WO1999022659A1 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1189544A2 (en) * 1999-06-03 2002-03-27 C.R. Bard, Inc. Method and apparatus for performing cardiac ablations
US9724170B2 (en) 2012-08-09 2017-08-08 University Of Iowa Research Foundation Catheters, catheter systems, and methods for puncturing through a tissue structure and ablating a tissue region
US9987081B1 (en) 2017-04-27 2018-06-05 Iowa Approach, Inc. Systems, devices, and methods for signal generation
US9999465B2 (en) 2014-10-14 2018-06-19 Iowa Approach, Inc. Method and apparatus for rapid and safe pulmonary vein cardiac ablation
US10130423B1 (en) 2017-07-06 2018-11-20 Farapulse, Inc. Systems, devices, and methods for focal ablation
US10172673B2 (en) 2016-01-05 2019-01-08 Farapulse, Inc. Systems devices, and methods for delivery of pulsed electric field ablative energy to endocardial tissue
US10322286B2 (en) 2016-01-05 2019-06-18 Farapulse, Inc. Systems, apparatuses and methods for delivery of ablative energy to tissue
US10433906B2 (en) 2014-06-12 2019-10-08 Farapulse, Inc. Method and apparatus for rapid and selective transurethral tissue ablation
US10507302B2 (en) 2016-06-16 2019-12-17 Farapulse, Inc. Systems, apparatuses, and methods for guide wire delivery
US10512505B2 (en) 2018-05-07 2019-12-24 Farapulse, Inc. Systems, apparatuses and methods for delivery of ablative energy to tissue
US10517672B2 (en) 2014-01-06 2019-12-31 Farapulse, Inc. Apparatus and methods for renal denervation ablation
US10531913B2 (en) 2010-07-30 2020-01-14 Boston Scientific Scimed, Inc. RF electrodes on multiple flexible wires for renal nerve ablation
US10617867B2 (en) 2017-04-28 2020-04-14 Farapulse, Inc. Systems, devices, and methods for delivery of pulsed electric field ablative energy to esophageal tissue
US10624693B2 (en) 2014-06-12 2020-04-21 Farapulse, Inc. Method and apparatus for rapid and selective tissue ablation with cooling
US10625080B1 (en) 2019-09-17 2020-04-21 Farapulse, Inc. Systems, apparatuses, and methods for detecting ectopic electrocardiogram signals during pulsed electric field ablation
US10660702B2 (en) 2016-01-05 2020-05-26 Farapulse, Inc. Systems, devices, and methods for focal ablation
US10687892B2 (en) 2018-09-20 2020-06-23 Farapulse, Inc. Systems, apparatuses, and methods for delivery of pulsed electric field ablative energy to endocardial tissue
US10842572B1 (en) 2019-11-25 2020-11-24 Farapulse, Inc. Methods, systems, and apparatuses for tracking ablation devices and generating lesion lines
US10893905B2 (en) 2017-09-12 2021-01-19 Farapulse, Inc. Systems, apparatuses, and methods for ventricular focal ablation
US11020180B2 (en) 2018-05-07 2021-06-01 Farapulse, Inc. Epicardial ablation catheter
US11033236B2 (en) 2018-05-07 2021-06-15 Farapulse, Inc. Systems, apparatuses, and methods for filtering high voltage noise induced by pulsed electric field ablation
US11065047B2 (en) 2019-11-20 2021-07-20 Farapulse, Inc. Systems, apparatuses, and methods for protecting electronic components from high power noise induced by high voltage pulses
US11259869B2 (en) 2014-05-07 2022-03-01 Farapulse, Inc. Methods and apparatus for selective tissue ablation
US11432870B2 (en) 2016-10-04 2022-09-06 Avent, Inc. Cooled RF probes
US11497541B2 (en) 2019-11-20 2022-11-15 Boston Scientific Scimed, Inc. Systems, apparatuses, and methods for protecting electronic components from high power noise induced by high voltage pulses

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986300B2 (en) * 2012-06-25 2015-03-24 Biosense Webster (Israel) Ltd. Irrigated electrodes with enhanced heat conduction
JP6059945B2 (en) * 2012-10-23 2017-01-11 株式会社カネカ Tip loop type electrode sweater

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4817608A (en) 1987-05-29 1989-04-04 Mieczyslaw Mirowski Cardioverting transvenous catheter/patch electrode system and method for its use
US5354297A (en) * 1992-02-14 1994-10-11 Boaz Avitall Biplanar deflectable catheter for arrhythmogenic tissue ablation
WO1997017030A1 (en) * 1995-11-10 1997-05-15 C.R. Bard, Inc. Snap-fit distal assembly for an ablation catheter
WO1997020510A1 (en) * 1995-12-08 1997-06-12 C.R. Bard, Inc. Radio frequency energy delivery system for multipolar electrode catheters
US5685978A (en) * 1994-11-14 1997-11-11 Petrick; Harold W. Reclaiming the constituent components of separating and uncured concrete
US5779669A (en) 1996-10-28 1998-07-14 C. R. Bard, Inc. Steerable catheter with fixed curve

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4817608A (en) 1987-05-29 1989-04-04 Mieczyslaw Mirowski Cardioverting transvenous catheter/patch electrode system and method for its use
US5354297A (en) * 1992-02-14 1994-10-11 Boaz Avitall Biplanar deflectable catheter for arrhythmogenic tissue ablation
US5685978A (en) * 1994-11-14 1997-11-11 Petrick; Harold W. Reclaiming the constituent components of separating and uncured concrete
WO1997017030A1 (en) * 1995-11-10 1997-05-15 C.R. Bard, Inc. Snap-fit distal assembly for an ablation catheter
US5685878A (en) 1995-11-13 1997-11-11 C.R. Bard, Inc. Snap fit distal assembly for an ablation catheter
WO1997020510A1 (en) * 1995-12-08 1997-06-12 C.R. Bard, Inc. Radio frequency energy delivery system for multipolar electrode catheters
EP0866675A1 (en) 1995-12-08 1998-09-30 C.R. Bard Inc. Radio frequency energy delivery system for multipolar electrode catheters
US5779669A (en) 1996-10-28 1998-07-14 C. R. Bard, Inc. Steerable catheter with fixed curve

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1189544A4 (en) * 1999-06-03 2003-02-05 Bard Inc C R Method and apparatus for performing cardiac ablations
US6616655B1 (en) 1999-06-03 2003-09-09 C. R. Bard, Inc. Method and apparatus for performing cardiac ablations
USRE42724E1 (en) 1999-06-03 2011-09-20 C.R. Bard, Inc. Method and apparatus for performing cardiac ablations
EP1189544A2 (en) * 1999-06-03 2002-03-27 C.R. Bard, Inc. Method and apparatus for performing cardiac ablations
US10531913B2 (en) 2010-07-30 2020-01-14 Boston Scientific Scimed, Inc. RF electrodes on multiple flexible wires for renal nerve ablation
US9724170B2 (en) 2012-08-09 2017-08-08 University Of Iowa Research Foundation Catheters, catheter systems, and methods for puncturing through a tissue structure and ablating a tissue region
US9861802B2 (en) 2012-08-09 2018-01-09 University Of Iowa Research Foundation Catheters, catheter systems, and methods for puncturing through a tissue structure
US11426573B2 (en) 2012-08-09 2022-08-30 University Of Iowa Research Foundation Catheters, catheter systems, and methods for puncturing through a tissue structure and ablating a tissue region
US10517672B2 (en) 2014-01-06 2019-12-31 Farapulse, Inc. Apparatus and methods for renal denervation ablation
US11589919B2 (en) 2014-01-06 2023-02-28 Boston Scientific Scimed, Inc. Apparatus and methods for renal denervation ablation
US11259869B2 (en) 2014-05-07 2022-03-01 Farapulse, Inc. Methods and apparatus for selective tissue ablation
US11241282B2 (en) 2014-06-12 2022-02-08 Boston Scientific Scimed, Inc. Method and apparatus for rapid and selective transurethral tissue ablation
US10624693B2 (en) 2014-06-12 2020-04-21 Farapulse, Inc. Method and apparatus for rapid and selective tissue ablation with cooling
US11622803B2 (en) 2014-06-12 2023-04-11 Boston Scientific Scimed, Inc. Method and apparatus for rapid and selective tissue ablation with cooling
US10433906B2 (en) 2014-06-12 2019-10-08 Farapulse, Inc. Method and apparatus for rapid and selective transurethral tissue ablation
US9999465B2 (en) 2014-10-14 2018-06-19 Iowa Approach, Inc. Method and apparatus for rapid and safe pulmonary vein cardiac ablation
US10835314B2 (en) 2014-10-14 2020-11-17 Farapulse, Inc. Method and apparatus for rapid and safe pulmonary vein cardiac ablation
US10433908B2 (en) 2016-01-05 2019-10-08 Farapulse, Inc. Systems, devices, and methods for delivery of pulsed electric field ablative energy to endocardial tissue
US10709891B2 (en) 2016-01-05 2020-07-14 Farapulse, Inc. Systems, apparatuses and methods for delivery of ablative energy to tissue
US11589921B2 (en) 2016-01-05 2023-02-28 Boston Scientific Scimed, Inc. Systems, apparatuses and methods for delivery of ablative energy to tissue
US10842561B2 (en) 2016-01-05 2020-11-24 Farapulse, Inc. Systems, devices, and methods for delivery of pulsed electric field ablative energy to endocardial tissue
US10172673B2 (en) 2016-01-05 2019-01-08 Farapulse, Inc. Systems devices, and methods for delivery of pulsed electric field ablative energy to endocardial tissue
US11020179B2 (en) 2016-01-05 2021-06-01 Farapulse, Inc. Systems, devices, and methods for focal ablation
US10660702B2 (en) 2016-01-05 2020-05-26 Farapulse, Inc. Systems, devices, and methods for focal ablation
US10512779B2 (en) 2016-01-05 2019-12-24 Farapulse, Inc. Systems, apparatuses and methods for delivery of ablative energy to tissue
US10322286B2 (en) 2016-01-05 2019-06-18 Farapulse, Inc. Systems, apparatuses and methods for delivery of ablative energy to tissue
US10507302B2 (en) 2016-06-16 2019-12-17 Farapulse, Inc. Systems, apparatuses, and methods for guide wire delivery
US11432870B2 (en) 2016-10-04 2022-09-06 Avent, Inc. Cooled RF probes
US9987081B1 (en) 2017-04-27 2018-06-05 Iowa Approach, Inc. Systems, devices, and methods for signal generation
US11357978B2 (en) 2017-04-27 2022-06-14 Boston Scientific Scimed, Inc. Systems, devices, and methods for signal generation
US10016232B1 (en) 2017-04-27 2018-07-10 Iowa Approach, Inc. Systems, devices, and methods for signal generation
US11833350B2 (en) 2017-04-28 2023-12-05 Boston Scientific Scimed, Inc. Systems, devices, and methods for delivery of pulsed electric field ablative energy to esophageal tissue
US10617867B2 (en) 2017-04-28 2020-04-14 Farapulse, Inc. Systems, devices, and methods for delivery of pulsed electric field ablative energy to esophageal tissue
US10617467B2 (en) 2017-07-06 2020-04-14 Farapulse, Inc. Systems, devices, and methods for focal ablation
US10130423B1 (en) 2017-07-06 2018-11-20 Farapulse, Inc. Systems, devices, and methods for focal ablation
US10893905B2 (en) 2017-09-12 2021-01-19 Farapulse, Inc. Systems, apparatuses, and methods for ventricular focal ablation
US11020180B2 (en) 2018-05-07 2021-06-01 Farapulse, Inc. Epicardial ablation catheter
US11033236B2 (en) 2018-05-07 2021-06-15 Farapulse, Inc. Systems, apparatuses, and methods for filtering high voltage noise induced by pulsed electric field ablation
US10709502B2 (en) 2018-05-07 2020-07-14 Farapulse, Inc. Systems, apparatuses and methods for delivery of ablative energy to tissue
US10512505B2 (en) 2018-05-07 2019-12-24 Farapulse, Inc. Systems, apparatuses and methods for delivery of ablative energy to tissue
US10687892B2 (en) 2018-09-20 2020-06-23 Farapulse, Inc. Systems, apparatuses, and methods for delivery of pulsed electric field ablative energy to endocardial tissue
US10625080B1 (en) 2019-09-17 2020-04-21 Farapulse, Inc. Systems, apparatuses, and methods for detecting ectopic electrocardiogram signals during pulsed electric field ablation
US10688305B1 (en) 2019-09-17 2020-06-23 Farapulse, Inc. Systems, apparatuses, and methods for detecting ectopic electrocardiogram signals during pulsed electric field ablation
US11738200B2 (en) 2019-09-17 2023-08-29 Boston Scientific Scimed, Inc. Systems, apparatuses, and methods for detecting ectopic electrocardiogram signals during pulsed electric field ablation
US11065047B2 (en) 2019-11-20 2021-07-20 Farapulse, Inc. Systems, apparatuses, and methods for protecting electronic components from high power noise induced by high voltage pulses
US11497541B2 (en) 2019-11-20 2022-11-15 Boston Scientific Scimed, Inc. Systems, apparatuses, and methods for protecting electronic components from high power noise induced by high voltage pulses
US11684408B2 (en) 2019-11-20 2023-06-27 Boston Scientific Scimed, Inc. Systems, apparatuses, and methods for protecting electronic components from high power noise induced by high voltage pulses
US11931090B2 (en) 2019-11-20 2024-03-19 Boston Scientific Scimed, Inc. Systems, apparatuses, and methods for protecting electronic components from high power noise induced by high voltage pulses
US10842572B1 (en) 2019-11-25 2020-11-24 Farapulse, Inc. Methods, systems, and apparatuses for tracking ablation devices and generating lesion lines

Also Published As

Publication number Publication date
CA2308278A1 (en) 1999-05-14
JP2001521774A (en) 2001-11-13

Similar Documents

Publication Publication Date Title
WO1999022659A1 (en) Ring electrode structure for diagnostic and ablation catheters
US10709501B2 (en) Catheter and method for improved ablation
US5447529A (en) Method of using endocardial impedance for determining electrode-tissue contact, appropriate sites for arrhythmia ablation and tissue heating during ablation
Langberg et al. Radiofrequency catheter ablation: the effect of electrode size on lesion volume in vivo
US5891138A (en) Catheter system having parallel electrodes
US6023638A (en) System and method for conducting electrophysiological testing using high-voltage energy pulses to stun tissue
US6107699A (en) Power supply for use in electrophysiological apparatus employing high-voltage pulses to render tissue temporarily unresponsive
EP2736434B1 (en) Intracardiac tool for delivery of electroporation therapies
EP0866675B1 (en) Radio frequency energy delivery system for multipolar electrode catheters
US4641649A (en) Method and apparatus for high frequency catheter ablation
US20120232551A1 (en) Ablative treatment of the heart to improve patient outcomes following surgery
WO1999060923A1 (en) Electrophysiological treatment methods and apparatus employing high voltage pulse to render tissue temporarily unresponsive
JP2012517306A (en) Ablation catheter and method for electrically insulating heart tissue
US20080161799A1 (en) Position independent catheter
KR20220014803A (en) Automatically performing irreversible electroporation ablation during heart refractory period
JP4087251B2 (en) Ablation catheter
Lavergne et al. Transcatheter radiofrequency ablation of atrial tissue using a suction catheter
Kalbfleisch et al. Catheter ablation with radiofrequency energy: Biophysical aspects and clinical applications
Willems et al. Temperature-controlled slow pathway ablation for treatment of atrioventricular nodal reentrant tachycardia using a combined anatomical and electrogram guided strategy
Rosenbaum et al. Advanced radiofrequency catheter ablation in canine myocardium
US6443950B1 (en) Ablation lead for atrial flutter
MXPA00004221A (en) Ring electrode structure for diagnostic and ablation catheters
Schwartz et al. Electrogram patterns associated with successful radiofrequency ablation of accessory pathways in children
HAINES et al. New horizons in catheter ablation
Singer et al. Nonpharmacological therapy of supraventricular arrhythmias: Surgery and catheter ablation techniques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2308278

Country of ref document: CA

Kind code of ref document: A

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2000 518602

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/004221

Country of ref document: MX

Ref document number: 1998957588

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998957588

Country of ref document: EP